Dimeric bacteriophage lysins
AssigneeThe Rockefeller University
InventorsVincent A. Fischetti, Gregory Resch
Life of this patent
Estimating the term…
Abstract
The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
Claims18
An isolated dimeric Streptococcus-specific phage lysin comprising two Streptococcus-specific phage lysin monomers covalently linked to each other, wherein said dimer has killing activity against one or more Streptococcus bacteria that is greater than the killing activity of any one of the Streptococcus-specific phage lysin monomers, and wherein each lysin monomer is mutated to contain a Cys residue between 14 and 20 amino acids from the C-terminus.
An isolated dimeric Streptococcus-specific phage lysin comprising two Streptococcus-specific phage lysin monomers covalently linked to each other, wherein said dimer has killing activity against one or more Streptococcus bacteria that is greater than the killing activity of any one of the Streptococcus-specific phage lysin monomers, and wherein said lysin monomers are selected from Cpl-1 monomer having at least 90% amino acid sequence identity to unmutated Cpl-1 having the amino acid sequence SEQ ID NO:
- 1 and Pal monomer having at least 90% amino acid sequence identity to unmutated Pal having the amino acid sequence SEQ ID NO:
- 5, wherein each lysin monomer is mutated to contain a Cys residue between 14 and 20 amino acids from the C-terminus.
Dependencies are inferred from the claim text.